KRTAP10-3: A Potential Drug Target and Biomarker (G386682)

Target Name: KRTAP10-3

NCBI ID: G386682

KRTAP10-3

KRTAP10-3: A Potential Drug Target and Biomarker

KRTAP10-3, also known as KRTAP18.3, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is Kallikrein-related protein 10.3, and it is a member of the kallikrein family of proteins. This protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The kallikrein family of proteins plays a crucial role in the regulation of proteostasis, which is the balance of protein synthesis and degradation in cells. Kallikrein-related proteins are involved in the regulation of a wide range of physiological processes, including blood clotting, inflammation, and pain perception.

KRTAP10-3 is a 12-kDa protein that is expressed in the brain, heart, and kidneys. It is highly conserved, with a calculated pI of 5.9, which makes it a potential target for small molecules. In addition, KRTAP10-3 is known to be involved in the regulation of angiogenesis, which is the formation of new blood vessels, and it is also involved in the regulation of inflammation.

Studies have shown that KRTAP10-3 is involved in the regulation of blood clotting, which is a critical function for maintaining cardiovascular health. KRTAP10-3 has been shown to regulate the activity of several enzymes involved in blood clotting, including the coagulation factors II, VII, IX, and X. It has also been shown to interact with several intracellular signaling pathways, including the TGF-β pathway.

In addition to its role in blood clotting, KRTAP10-3 is also involved in the regulation of neurodegenerative diseases. Studies have shown that KRTAP10-3 is involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of neuronal excitability. This suggests that KRTAP10-3 may be a potential target for drugs that can treat neurodegenerative diseases.

KRTAP10-3 has also been shown to be involved in the regulation of autoimmune disorders. Studies have shown that KRTAP10-3 is involved in the regulation of immune cell function, including the regulation of T cell proliferation and differentiation. This suggests that KRTAP10-3 may be a potential target for drugs that can treat autoimmune disorders.

In conclusion, KRTAP10-3 is a protein that is expressed in various tissues of the body and is involved in a wide range of physiological processes, including blood clotting, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target and biomarker makes it an attractive target for research into new treatments for a variety of diseases. Further studies are needed to fully understand the role of KRTAP10-3 in these processes and to develop effective treatments.

Protein Name: Keratin Associated Protein 10-3

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP10-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP10-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets